Arteriovenous carbon dioxide removal (AVCO 2 R) as an alternative treatment for acute respiratory distress syndrome uses a low resistance gas exchanger in a simple arteriovenous shunt to achieve total CO 2 removal and allow lung rest. We have previously shown in our clinically relevant LD 40 ovine model of smoke/burn induced acute respiratory distress syndrome that AVCO 2 R allows significant decreases in respiratory rate, tidal volume, peak airway pressure, and FiO 2 , as compared with standard mechanical ventilation. In addition, we have shown in a prospective randomized outcomes study that AVCO 2 R increases ventilator free days, decreases ventilator dependent days, and significantly improves survival. The purpose of this study is to further define the limits of AVCO 2 R through hemodynamic augmentation and evaluation of peak end expiratory pressure (PEEP). Administration of an alpha agonist (phenylephrine) and a beta agonist (isoproterenol) increased mean arterial pressure (MAP) and cardiac output (CO), respectively. MAP increases ranged from 2.4% to 94.4% and CO increases ranged from 33% to 146%. Phenylephrine caused elevations in MAP (2.4 -94.4%) and AVCO 2 R flow (9 -67%), and CO never decreased more than 10%. Isoproterenol administration increased CO (33-146%), decreased MAP (9 -54%), and decreased AVCO 2 R flow (11-42%). In a second group, PEEP was increased stepwise from 0 (baseline) to 20 cm H 2 O. Increasing PEEP did not result in significant hemodynamic changes (<10% change from baseline PEEP) for MAP, CO, or AVCO 2 R flow. In conclusion, alpha agonist administration increased AVCO 2 R blood flow, whereas beta agonist administration decreased MAP and AVCO 2 R blood flow, despite CO elevation. Various levels of PEEP are well tolerated and thus allow a range of options during AVCO 2 R.
Patients with acute respiratory distress syndrome (ARDS) currently comprise approximately 16 -18% of the intensive care unit mechanically ventilated population. 1 Mortality for ARDS has been reported to be between 40 -60%, [2] [3] [4] [5] with the most recent surveys showing rates as low as 34 -36%. 6, 7 Efforts to reduce the high mortality rates associated with ARDS have focused on ventilator strategies aimed at restoring normal blood gases and allowing lung rest while minimizing ventilator induced lung injury. Elevated airway volumes and pressures induce baro/volutrauma to the lungs, 8 -12 and less aggressive ventilation results in a rise in systemic arterial CO 2 levels (permissive hypercapnia). [13] [14] [15] [16] The use of peak end expiratory pressure (PEEP) in conjunction with low tidal volume/low pressure ventilation is the current standard. 17 PEEP prevents the collapsing of alveoli during expiration, decreasing ventilator induced lung injury and increasing oxygenation. However, opinions as to how much PEEP is optimal has ranged from least PEEP (the minimal PEEP required to maintain PaO 2 above 60 mm Hg on 0.5 FiO 2 ) 18 to super PEEP (PEEP Ͼ 15 cm H 2 O). 19, 20 We have recently shown in a prospective randomized outcomes study in an LD 40 sheep model of ARDS 21 that arteriovenous carbon dioxide removal (AVCO 2 R) allows significant reductions in respiratory rate, tidal volume, peak airway pressure, and FiO 2 compared with standard mechanical ventilation. 12 In addition, AVCO 2 R reduced ventilator dependent days and significantly improved survival. 22 Our previous studies demonstrated that AVCO 2 R is blood flow dependent. 9, 23 The purpose of this study was to define the limits of AVCO 2 R blood flow by manipulating mean arterial pressure (MAP), cardiac output (CO), and PEEP (5-20 cm H 2 O) in our LD 40 smoke/burn induced sheep model of ARDS. Our goal was to define patient management strategies to augment AVCO 2 R gas exchange during the treatment of ARDS.
Materials and Methods
All animals received humane care according to Guide for the Care and Use of Laboratory Animals (2085) prepared by the US Department of Health and Human Services and published by the National Institutes of Health. The study was approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Texas Medical Branch, Galveston, Texas, with strict adherence to IACUC guidelines regarding the humane use of animals.
Adult Suffolk ewes (34 -40 kg, n ϭ 5) were used to investigate the effects of an alpha agonist (phenylephrine) and beta agonist (isoproterenol) on shunt blood flow, MAP, HR, and CO over a 48 hour treatment period. A separate group of animals (n ϭ 3) were used to evaluate the effects of increasing levels of PEEP on MAP, CO, and AVCO 2 R blood flow. All investigations used our clinically pertinent LD 40 large animal model of ARDS. Hemodynamic variables and ventilator settings were recorded every 6 hours. Airway suctioning and lavage was performed every 4 -6 hours to remove proteinaceous bronchial casts.
Once ARDS entry criteria was met (PaO 2 /FiO 2 Ͻ 200), animals were reanesthetized, systemically anticoagulated (300 IU/kg bovine lung heparin) (Upjohn, Kalamazoo, MI), and started on antibiotics therapy (ampicillin, 1 gm; gentamicin, 80 mg/ml). Animals then underwent cannulation of the left carotid artery (percutaneous 10 -12 Fr. TF018LH, Research Medical, Midvale, UT) and the left jugular vein (percutaneous 14 -16 Fr. TF022L, Research Medical). A low resistance membrane gas exchanger (Affinity, Avecor Cardiovascular, Plymouth, MN) was primed with normal saline (270 ml) and connected to the vascular cannulae after de-airing. Activated clotting time (Hemochron 400, International Technidyne, Edison, NJ) was maintained between 300 -500 seconds with a continuous heparin infusion throughout the study. The animal was then allowed to recover with free access to food and water and then placed on a volume controlled ventilator (Bear 1000 Ventila-tor, Bear Medical Systems Inc., Riverside, CA) before initiation of AVCO 2 R.
Animals were allowed a minimum of 24 hours to rest and stabilize after AVCO 2 R placement. Once stable, baseline measurements were obtained to represent hemodynamic status before augmentation and thus serve as the study control. Rate controlled intravenous infusion was then increased to achieve stepwise increases in MAP via phenylephrine and CO via isoproterenol. Hemodynamics, gas exchange, and ventilator parameters were recorded at intervals based on percent increases from baseline measurements. Once iv infusion was discontinued, animals were allowed to return to baseline before the experiment was repeated.
Standard dosages of both phenylephrine and isoproterenol for continuous iv infusion were used in this study. The starting dose and the concentration at maximal effect were recorded to ensure that drug administration did not exceed toxic levels. The appropriate data to create true dose response curves for phenylephrine and isoproterenol were not recorded in this study but will be included in all future studies.
PEEP was increased in increments of 5 cm H 2 O from 0 to 20, and MAP, CO, and AVCO 2 R blood flow were recorded. Control data were obtained at 0 cm H 2 O of PEEP. At the beginning of each trial (33 total runs), PEEP was initially started at 0 cm H 2 O.
Results
Over 400 hours of bedside critical care and data collection were required for the sheep in this study. Data were collected over a 48 hour period after AVCO 2 R placement. Phenylephrine administration increased MAP from 2.4% to 94.4% of baseline without significant compromise in CO (9.4% of baseline at 95% increase in MAP). The elevation in MAP produced increased flow through the AVCO 2 R device up to 67% of baseline (Figure 1) .
Isoproterenol infusion yielded a rise in CO from baseline (33-146%), but resulted in decreases in MAP (9 -54%) and AVCO 2 R blood flow (11-42%) (Figure 2) . When CO was doubled (2ϫ baseline), MAP and AVCO 2 R blood flow dropped 32 and 34% respectively. CO 2 removal remained constant throughout the study. For evaluation of PEEP, endpoints were calculated as percent changes from baseline during PEEP of 5, 10, 15, and 20 cm H 2 O. Despite these levels of PEEP, AVCO 2 R flow never decreased more than 2.7% from baseline at zero PEEP.
Discussion
With AVCO 2 R now under evaluation for the treatment of ARDS in clinical trials, our goal is to develop CO 2 removal strategies to augment AVCO 2 R performance. We previously reported that normal PaO 2 and PaCO 2 could be maintained with minimal ventilator support (rate 2-4 min, peak inspiratory pressure Ͻ 25 mm Hg) at an AVCO 2 R blood flow of 500 ml/min or higher. 9 In addition, CO 2 removal increased proportionally to AVCO 2 R blood flow to a maximum of 1.4 L/min or 19% of CO. 9 During ARDS, CO 2 production can result in marked hypercapnia, necessitating strategies to increase CO 2 removal to maintain normocapnia or moderate hypercapnia. Likewise, reduction in extracorporeal flow at reduced minute ventilation leads to the development of hypercapnia if flow is less than 10% of CO (Figure 3) . 24 Increasing CO or MAP by pharmacologic intervention may restore adequate AVCO 2 R flow to achieve near total CO 2 removal. The purpose of this study was to evaluate the effect of a pure alpha and pure beta agonist on AVCO 2 R blood flow and evaluate AVCO 2 R performance during increasing levels of PEEP.
We found that infusion of the alpha agonist resulted in increased blood flow proportional to the rise in MAP. Beta agonist infusion resulted in an increase in CO and HR but a decline in MAP and AVCO 2 R blood flow. The results of this study can be explained by the laws of fluid mechanics. Flow through the AVCO 2 R device can be expressed as:
where Q is blood flow, ⌬P is pressure drop between MAP and central venous pressure, and R is the resistance of the AVCO 2 R circuit (oxygenator and associated cannulas). Resistance through the shunt is crucial for adequate blood flow. The pressure across the device is less than 10 mm Hg as reported previously 12 and confirmed in this study. Because tubing resistance is one of the rate limiting factors for blood flow through an arteriovenous shunt, 25 low resistance percutaneous cannulas are used during AVCO 2 R. 26 Additionally, systemic venous resistance is minimized by using cannulae four French sizes larger than their paired arterial cannulae. 26 Once the device is in place, resistance remains constant, and blood flow is determined primarily by systemic arterial pressure. When phenylephrine was infused, the systemic pressure increased and resulted in higher AVCO 2 R flow rates. The resistance of the AVCO 2 R circuit can be calculated from the collected values for MAP and AVCO 2 R flow using the above equation. The calculated resistance is 18,261 dynes and is represented by the slope of the line in Figure 4 . During isoproterenol infusion, both ␤ 1 and ␤ 2 receptors are stimulated, resulting in increased heart rate and contractility in addition to vasodilation of skeletal muscle arterioles. ␤ 2 induced vasodilation decreases both systemic vascular resistance and afterload on the heart, thus contributing to the elevation in CO. As the systemic vascular resistance decreases, blood flow is increasingly diverted from the fixed resistance of the AVCO 2 R shunt. The cumulative effect is a drop in MAP and a decrease in AVCO 2 R blood flow. AVCO 2 R performance was not affected by the stepwise increases in PEEP to 20 cm H 2 O. The maximum increase in MAP (9.6%) was not enough to result in a significant change in AVCO 2 R blood flow (2.7%). Likewise, the increasing PEEP did not significantly decrease CO, with only a 3.2% decrease at maximum PEEP (20 cm H 2 O). MAP, mean arterial pressure; CO, cardiac output; AVCO 2 R, arteriovenous carbon dioxide removal; PEEP, peak end expiratory pressure.
Conclusions
The CO 2 removal performance of AVCO 2 R is dependent upon circuit blood flow. As predicted by fluid mechanics, pressure is essential in maintaining the driving force for blood flow through the circuit. The alpha agonist proved to be more effective than the beta agonist at elevating MAP and augmenting flow through the shunt. In addition, AVCO 2 R performance is not affected by increasing PEEP (up to 20 cm H 2 O), allowing freedom to make adjustments during ventilator management of patients' with ARDS.
